Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.



Status:Recruiting
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:12 - Any
Updated:4/2/2016
Start Date:January 2006
End Date:March 2019
Contact:Paul J Pinciaro, PhD
Email:paul.pinciaro@grifols.com
Phone:410-814-7617

Use our guide to learn which trials are right for you!

A Phase II/III Pivotal Trial Evaluating the Safety, Pharmacokinetic Properties and Efficacy of a Plasma-Derived Anti-thrombin III Concentrate With Administration in Surgery, Pregnancy and Thromboembolic or Thrombotic Events.

To assess the safety, pharmacokinetics and efficacy of a plasma-derived AT-III concentrate
in the treatment of subjects with congenital AT-III deficiency.

This study will be a prospective, unblinded, non-randomized, open-label, multi-center Phase
II/III study with 2 segments, i.e. a PK evaluation (Segment I), and an assessment of
prophylaxis in surgical interventions and pregnancy/delivery, (Segment II). During the PK
segment, the subjects would remain on their current anticoagulation therapy except for
subjects on heparin therapy where a wash-out period of at least 5 half lives would be
required. In total, 15 subjects with congenital ATIII Deficiency will be enrolled for the PK
assessment (Segment I).

For Segment II, fifteen episodes will be treated. Recruitment of individual subjects with
high risk for venous thrombosis for Segment II of this study is necessary because of the
rarity of Antithrombin deficiency in the population.

Inclusion Criteria:

- Congenital ATIII deficiency documented by determination of plasma levels of ATIII off
all therapies. Specifically, the baseline levels of ATIII activity should be equal to
or less than 60%.

- Age > 12 years with a body weight of no less than 30 kg.

- Have not participated in another investigational study for at least 30 days For
Segment II, enrollment requires a pregnancy/delivery or a surgical procedure (it
should be a major surgery although data from a minor surgery will also be collected).

- Documented personal history of major thromboembolic or thrombotic event.

- Male or female

- HIV, HBV, HCV, HAV and PARVO B19 status known prior to entry.

- The subject is willing to comply with all aspects of the protocol, including blood
sampling, for the duration of the study.

- The subject has signed an informed consent form (if at least 18 years old), or the
subject's parent or legal guardian has signed the informed consent form. Subjects
below the age of 18 years will also be asked to sign an assent form. All consent and
assent forms must be approved in advance by the Institutional Review Board of the
investigator's institution.

- Patients with heparin-associated thrombocytopenia who require anticoagulation with
non-heparin containing drugs will be eligible if they can be safely transitioned
during the washout period for the Segment I PK study.

- If pregnant, a woman must be Parvo B19 IgG antibody positive.

Exclusion Criteria:

- Acquired deficiency of ATIII

- Receiving concomitant treatment for thrombophilic disorders other than ATIII
deficiency

- Inability or unwillingness to comply with the protocol requirements

- History of anaphylactic reaction(s) to blood or blood components

- Allergies to excipients.

- Liver function tests >/= 2.5 X ULN

- Serum creatinine >1.2 X ULN

- Urine >/= 2+ protein with urine dipstick test.

- The subject is known to have abused alcohol or illicit drugs within the past 12
months.

- The subject is unlikely to adhere to the protocol requirements of the study or is
likely to be uncooperative or unable to provide a storage serum sample at the
screening visit.

- Patients on heparin-treatment who, for clinical reasons, cannot safely be
discontinued from heparin therapy during the PK segment.
We found this trial at
2
sites
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials